I would be fascinated to know the dispassionate opinion of this group on a quite large trial of HRT v nothing which appears to negate a great deal of evidence from other RCT's on the effect of HRT
on CVD and breast cancer in particular.
It is not blind (does that matter and how much). It is funded by HRT Pharma, most of the PI's have advisory roles with the companies. 8% of eligible patients were recruited into the trial ………..
Where should it sit in the panoply of evidence on the safety of HRT ??
This is an important question because of the unambiguous and profound benefits of HRT for menopausal symptoms but particularly bone density loss, and hence the 'need' to downplay possible harms.
Your opinions would be greatly valued.
Klim McPherson MA Phd FFPH FMedSci
Visiting Professor of Public Health Epidemiology
Nuffield Dept Obstetrics & Gynaecology
Emeritus Fellow of New College
University of Oxford
Mobile 07711335993